Breaking News

Maryland's COVID-19 Vaccine Sold Thirty-One Million Doses Globally

May 10, 2022 • 6:06 pm CDT
by aroblesgalit
(Precision Vaccinations)

Maryland-based Novavax, Inc. announced its operational highlights for the first quarter of 2022, which confirmed that the company sold 31 million protein-based NVX-CoV2373 COVID-19 vaccine doses and produced $19 million of royalties and adjuvant sales to partners.

Novavax continues to expect to achieve its full-year 2022 total revenue target of between $4 and $5 billion. 

Additionally, Novavax stated on May 9, 2022, that it continued label expansion (Nuvaxovid, CovoVax), including primary, booster, and adolescent authorizations and new shipments of Nuvaxovid™ into the European Union, Canada, South Korea, Australia, Thailand, Singapore, and New Zealand.

Existing authorizations leverage Novavax' vaccine manufacturing partnership with Serum Institute of India, the world's largest vaccine manufacturer by volume. 

Furthermore, the company successfully submitted an authorization request to U.S. FDA, which enabled the FDA to schedule a review meeting for June 7, 2022.

"Novavax has been successful in launching our protein-based COVID-19 vaccine worldwide and executing on our plans for ongoing label expansions for pediatrics and homologous and heterologous boosting. Reinforced by our first profitable quarter, with $704 million in revenue, we are continuing our robust commercial rollout," said Stanley C. Erck, President, and Chief Executive Officer, Novavax, in a related press release.

"Importantly, as new variants have emerged, we have progressed our strategy to be ready to address the dynamic environment and continue development beyond COVID-19 with our COVID-19-Influenza Combination vaccine candidate." 

Note(s): Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. 

The company's press statement was edited and manually curated for mobile readers.

Medical Review by
Share